PRODUCT INFORMATION

Vipadenant
Item No. 20239

CAS Registry No.: 442908-10-3
Formal Name: 3-[(4-amino-3-methylphenyl)methyl]-7-(2-furanyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine
Synonym: BIBB-014
MF: C_{16}H_{15}N_{7}O
FW: 321.3
Purity: ≥98%
UV/Vis.: λ_{max}: 231, 301, 349 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vipadenant is supplied as a crystalline solid. A stock solution may be made by dissolving the vipadenant in the solvent of choice. Vipadenant is soluble in the organic solvent DMSO, which should be purged with an inert gas, at a concentration of approximately 43 mg/ml.

Description

Vipadenant is a selective adenosine 2A (A_{2A}) receptor antagonist with K_{i} values of 1.3, 68, 63, and 1.005 nM for A_{2A}, A_{1}, A_{2B}, and A_{3} receptors, respectively, in a radioligand binding assay. It acts as a functional antagonist of human recombinant A_{2A} (K_{A} = 0.58 nM) in a calcium mobilization-based FLIPR assay. Vipadenant also reverses haloperidol-induced hypolocomotion in mice and rats. Formulations containing vipadenant are under clinical investigation for the treatment of symptoms associated with Parkinson’s disease.

References

2. Pinna, A. Adenosine A_{2A} receptor antagonists in Parkinson’s disease: Progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 28(5), 455-474 (2014).

Copyright Cayman Chemical Company, 09/19/2017